Soaring Eagle Acquisition Corp. (NASDAQ:SRNG) has secured shareholder approval of its combination with cell programming company Ginko Bioworks at a shareholder vote this morning.
The SPAC did see about 49% of its trust redeemed in the vote, however. This will still provide about $1.6 billion in proceeds to Ginko Bioworks, including $858 million from Soaring Eagle’s remaining trust, which is plenty to fulfill the transactions’ minimum cash condition of $1.25 billion. Overall, this is a better-than-average result compared to the redemption rates of the past month, but still more than might be expected for such a prestigious deal.
Soaring Eagle expects to complete the transaction on September 16. The combined company’s shares and warrants are expected to begin trading on the NYSE the following day under the symbols “DNA” and “DNA.WS”, respectively.
Ginko Bioworks uses genetic engineering to create bacteria for a range of industries with a focus on strain improvement, enzyme discovery, new product development, biosecurity, and mammalian cell engineering. Most recently, Ginko Bioworks announced its platform had achieved breakthroughs in manufacturing mRNA vaccines and rare forms of cannabis compounds.
About 75% of shares participated in Soaring Eagle’s vote and 97% voted in favor of the transaction. Vote tallies on any additional measures will be made available once the SPAC files its 8-K on the meeting.
ADVISORS
- Allen & Company LLC and Morgan Stanley & Co. LLC are acting as financial advisors to Ginkgo.
- Latham & Watkins LLP is acting as legal advisor to Ginkgo.
- Wachtell, Lipton, Rosen & Katz is acting as legal advisor to Ginkgo with respect to certain corporate governance matters.
- Goldman Sachs & Co. LLC is acting as financial advisor to Soaring Eagle.
- White & Case LLP is acting as legal advisor to Soaring Eagle.
- Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC, and Allen & Company LLC served as placement agents for Soaring Eagle on the PIPE transaction.
Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...
At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...
Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...
At the SPAC of Dawn Ever since Digital World announced its combination with Trump Media (NASDAQ:DJT) back in October 2021, it was clear that SPACworld and the Trump show were set to be intertwined for quite some time. And, although not every headline has a bearing on the wider SPAC world, Trump Media’s post-close rise...
AltC (NYSE:ALCC) has reportedly been taking the pitch deck for its combination with nuclear fission firm Oklo on the road in recent weeks, which has generated the rare result of a SPAC trading significantly above its trust value still well before completing its deal. The SPAC has an estimated $10.59 per share in its trust...